These myeloid malignancies arise due to acquired somatic stem cell lesions affecting calreticulin (CALR), myeloproliferative leukemia virus proto-oncogene (MPL), and the tyrosine kinase Janus kinase 2 (JAK2), usually displaying a valine-to-phenylalanine mutation at 617 (JAK2V617F) (7). This evidence concerns the gene CALR and myeloid neoplasm.